Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.

Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD.

Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000633. [Epub ahead of print]


EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD.

Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.


Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.

Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, Szustakowski JD.

PLoS One. 2017 Jul 27;12(7):e0179726. doi: 10.1371/journal.pone.0179726. eCollection 2017.


Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.

Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.


Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD.

Cancer Immun. 2013 May 1;13:7. Print 2013.


Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.

Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji RR.

J Transl Med. 2013 Mar 22;11:75. doi: 10.1186/1479-5876-11-75.


Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.

Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR.

Cancer Immunol Immunother. 2012 May;61(5):733-7. doi: 10.1007/s00262-012-1227-3. Epub 2012 Mar 1.


An immune-active tumor microenvironment favors clinical response to ipilimumab.

Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V.

Cancer Immunol Immunother. 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6. Epub 2011 Dec 7.


Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D.

J Immunother. 2012 Jan;35(1):89-97. doi: 10.1097/CJI.0b013e31823aa41c.


A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D.

J Transl Med. 2011 Nov 28;9:204. doi: 10.1186/1479-5876-9-204.


Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL.

Cancer Immun. 2010 Nov 24;10:11.


The genetic architecture of response to long-term artificial selection for oil concentration in the maize kernel.

Laurie CC, Chasalow SD, LeDeaux JR, McCarroll R, Bush D, Hauge B, Lai C, Clark D, Rocheford TR, Dudley JW.

Genetics. 2004 Dec;168(4):2141-55.


Supplemental Content

Loading ...
Support Center